Parkinson disease (PD) is the most common neurodegenerative movement disorder. In
Europe, prevalence and incidence rates for PD are estimated at approximately 108–257/100 …

The history of brain drug delivery is reviewed beginning with the first demonstration, in 1914,
that a drug for syphilis, salvarsan, did not enter the brain, due to the presence of a blood …

Alzheimer's disease (AD) and treatment of the brain in aging require the development of
new biologic drugs, such as recombinant proteins or gene therapies. Biologics are large …

Astrocytes are the most populous glial subtype and are critical for brain function. Despite
this, historically there have been few studies into the role that they may have in …

This article reviews and summarizes 200 years of Parkinson's disease. It comprises a
relevant history of Dr. James Parkinson's himself and what he described accurately and …

We investigated the effects of glial cell line-derived neurotrophic factor (GDNF) in
Parkinson's disease, using intermittent intraputamenal convection-enhanced delivery via a …

The tetracycline-controlled Tet-Off and Tet-On gene expression systems are used to regulate
the activity of genes in eukaryotic cells in diverse settings, varying from basic biological …

Despite the enormity of the societal and health burdens caused by Alzheimer's disease
(AD), there have been no FDA approvals for new therapeutics for AD since 2003. This …

Existing therapeutic strategies for managing Parkinson disease (PD), which focus on
addressing the loss of dopamine and dopaminergic function linked with degeneration of …

Poly (lactic-co-glycolic acid)(PLGA) is one of the most successfully developed
biodegradable polymers. Among the different polymers developed to formulate polymeric …